10-Q: Inogen Narrows Q3 Loss, Boosts Sales Amid Strategic Shifts

Inogen, Inc. reported a reduced net loss for the third quarter and nine months ended September 30, 2025, driven by increased sales revenue and lower operating expenses, despite declines in rental revenue and direct-to-consumer sales.

Summary

• Net loss for the three months ended September 30, 2025, decreased by 11.2% to $5.3 million from $6.0 million in the comparable prior-year period.
• Net loss for the nine months ended September 30, 2025, decreased by 40.2% to $15.6 million from $26.1 million in the comparable prior-year period.
• Total revenue for the three months ended September 30, 2025, increased by 4.0% to $92.4 million from $88.8 million in the comparable prior-year period.
• Total revenue for the nine months ended September 30, 2025, increased by 4.4% to $266.9 million from $255.6 million in the comparable prior-year period.
• Sales revenue for the three months ended September 30, 2025, grew by 5.6% to $79.1 million, with approximately 51,100 oxygen systems sold, an increase of 16.4%.
• Sales revenue for the nine months ended September 30, 2025, grew by 6.7% to $226.7 million, with approximately 143,100 oxygen systems sold, an increase of 20.2%.
• Rental revenue decreased by 4.4% to $13.3 million for the three months and by 6.9% to $40.2 million for the nine months, primarily due to a higher mix of lower private-payor reimbursement rates and fewer patients on service.
• Domestic direct-to-consumer sales decreased by 17.9% in the quarter and 22.0% for the nine months, driven by lower volume and average selling price.
• International business-to-business sales increased by 18.8% in the quarter and 19.6% for the nine months, primarily due to higher demand.
• Research and development expense increased by 37.6% to $4.8 million in the quarter but decreased by 10.4% to $14.1 million for the nine months.
• Sales and marketing expense decreased by 3.5% to $25.4 million in the quarter and by 5.5% to $74.6 million for the nine months.
• General and administrative expense decreased by 5.7% to $18.2 million in the quarter and by 6.7% to $51.3 million for the nine months.
• Cash and cash equivalents were $106.5 million as of September 30, 2025.
• Adjusted EBITDA for the nine months ended September 30, 2025, was $4.4 million, a significant improvement from a negative $5.9 million in the prior-year period.

Sentiment

Score: 7

Explanation: The company demonstrated significant improvement in net loss and positive revenue growth, particularly in business-to-business and international sales. Strategic initiatives like the Yuwell collaboration and new product launches (Simeox, Voxi 5) position it for future growth. However, declines in rental revenue and domestic direct-to-consumer sales, along with gross margin pressures and a negative operating cash flow for the nine months, temper the overall positive sentiment. The capital raise from Yuwell is a positive sign of strategic partnership and funding.

Positives

• Net loss significantly decreased by 11.2% for the three months and 40.2% for the nine months ended September 30, 2025, indicating improved financial performance.
• Total revenue increased by 4.0% for the quarter and 4.4% for the nine months, demonstrating overall business growth.
• Oxygen systems sold increased substantially by 16.4% in Q3 and 20.2% for the nine months, reflecting strong product demand.
• International business-to-business sales showed robust growth of 18.8% in Q3 and 19.6% for the nine months, highlighting successful global expansion efforts.
• Operating expenses, including sales and marketing, and general and administrative expenses, decreased for both periods, indicating effective cost management.
• A Strategic Collaboration Agreement with Yuwell is expected to broaden the product portfolio, enhance the innovation pipeline, and accelerate entry into the Chinese market.
• Obtained 510(k) clearance for the Simeox product in December 2024, opening a new revenue stream in the U.S. airway clearance market.
• Launched the Voxi 5 stationary oxygen concentrator in June 2025, diversifying product offerings.
• Cash and cash equivalents of $106.5 million as of September 30, 2025, provide a solid liquidity position.
• Net working capital increased to $138.8 million as of September 30, 2025, from $108.8 million as of December 31, 2024.

Negatives

• Rental revenue decreased by 4.4% in Q3 and 6.9% for the nine months, primarily due to a higher mix of lower private-payor reimbursement rates and fewer patients on service.
• Domestic direct-to-consumer sales decreased significantly by 17.9% in Q3 and 22.0% for the nine months, attributed to lower volume and average selling price.
• Gross margin on sales revenue decreased to 45.7% in Q3 2025 from 47.2% in Q3 2024, and to 45.1% for the nine months from 46.7%, driven by channel/customer mix and higher material cost premiums.
• Gross margin on rental revenue decreased to 38.7% in Q3 2025 from 43.2% in Q3 2024, and to 41.7% for the nine months from 44.4%, due to lower reimbursement rates and fewer patients.
• Legal settlement costs increased by $1.8 million in Q3 2025 due to the APT Action lawsuit.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $10.3 million, a significant negative swing compared to $8.9 million provided in the prior-year period.
• Exposure to foreign currency exchange risk, with a hypothetical 10% adverse change potentially resulting in an $8.4 million decline in revenue for the nine months ended September 30, 2025, prior to hedging activities.

Risks

• Impact of expense inflation on product components and the ability of customers to afford products.
• Potential for future supply chain constraints affecting manufacturing and distribution.
• Uncertainty regarding reimbursement rates, future rounds of competitive bidding, and changes by the Centers for Medicare and Medicaid Services (CMS).
• Ability to develop new products, improve existing products, and increase their value in a competitive market.
• Competitors introducing lower-priced products, products with more features, or products that are otherwise more accepted by the market.
• Ability to attract and retain key talent within the company.
• Challenges in efficiently integrating Physio-Assist and obtaining reimbursement coverage and payment for Simeox products in the U.S.
• Impact and implementation of trade regulations, including tariffs and export controls, on the supply chain.
• Foreign currency exchange risk due to a significant portion of non-U.S. revenue being invoiced in Euros.
• Litigation can have an adverse impact due to defense and settlement costs, diversion of management resources, and other factors.
• Reliance on a limited number of vendors for raw materials, with three major vendors accounting for 18.2%, 11.2%, and 10.2% of total raw material purchases for the nine months ended September 30, 2025.
• Liquidity assumptions may prove incorrect, leading to faster utilization of available financial resources.
• Future funding requirements depend on many factors, and additional funds may not be obtainable on acceptable terms, or at all, potentially diluting existing stockholders or imposing restrictive covenants.
• Operating performance below expectations could adversely affect liquidity and the ability to operate the business.

Future Outlook

The company expects its collaboration with Yuwell to broaden its product portfolio, enhance its innovation pipeline through research and development, and accelerate its brand entry into the Chinese market. A more extensive launch of the Voxi 5 stationary oxygen concentrator is planned for 2026, focusing on market development. The company intends to continue investments in respiratory product offerings to develop innovative products and expand clinical evidence, including clinical studies to evaluate improvements in clinical, economic, and patient-reported outcomes. It is focused on expanding new products that benefit patients, prescribers, and customers with a clinically relevant pipeline, including innovations in COPD and digital health value-added services, and expanding use to hypercapnia, shortness-of-breath, and other related disease indications. The company believes its current cash, cash equivalents, marketable securities, and cash from expected product sales and rentals will be sufficient to meet projected operating and investing requirements for at least the next 12 months.

Management Comments

• "We remain focused on our domestic business-to-business partnerships, including relationships with distributors, key accounts, resellers, our private label collaborator, and traditional HME providers."
• "We continue to believe there is a sizable international market opportunity, particularly in Europe where there is existing oxygen reimbursement for respiratory conditions."
• "We are continuing to focus on the patient first initiative, which involves cross-training of sales representatives to execute cash sales and insurance rental."
• "We expect to continue to focus on increased productivity driven by improved sales management discipline, insights-informed tools, and optimized patient lead generation with a downsized direct-to-consumer sales team."
• "We continue to evolve our operating model to focus the enhanced sales teams to drive increased rental revenue by establishing relationships with the prescriber through a consistent cadence of contact."
• "We intend to commercialize Simeox through the sale or rental of the product initially, followed by recurring sales of device disposables."
• "We initiated in June 2025 the launch of the Voxi 5, a new stationary oxygen concentrator designed to enhance access to high-quality oxygen therapy for long-term care patients. A more extensive launch of this product is planned in 2026 as we focus on market development."
• "In China, we continue to work through the registration process for our products."

Industry Context

The company operates in the medical technology sector, specializing in respiratory health, including portable oxygen concentrators and airway clearance devices. The market is influenced by evolving reimbursement rates, competitive product landscapes, and global supply chain dynamics. The company's strategic focus on expanding its product offerings (Simeox, Voxi 5) and penetrating international markets (Europe, Asia-Pacific, Latin America, China) aligns with broader industry trends of diversification and global reach. The collaboration with Yuwell exemplifies a growing trend of strategic partnerships to enhance product portfolios and market access. The decline in rental revenue due to lower private-payor reimbursement rates underscores the ongoing pressures and complexities within the U.S. healthcare reimbursement environment.

Legal Proceedings

• APT Electronics Inc. filed a lawsuit against the company on March 3, 2023, alleging failure to pay for services, inventory, and materials.
• The parties reached a mutually agreeable settlement in August 2025, with the company paying $1,750 thousand to APT and incurring $668 thousand in legal settlement costs.
• The court dismissed the APT Action with prejudice on August 27, 2025.
• The company is party to various other legal proceedings and investigations arising in the normal course of business, but does not anticipate a material adverse effect from these.

Related Party Transactions

• The company entered into a Strategic Collaboration Agreement and a Securities Purchase Agreement with Yuwell (Hong Kong) Holdings Limited, a wholly-owned subsidiary of Yuwell, on January 25, 2025.
• Yuwell (Hong Kong) Holdings Limited purchased 2,626,425 shares of the company's common stock for approximately $27.2 million in a private placement that closed on February 21, 2025.
• The collaboration involves mutual distribution of products in specified territories and research and development collaboration.

Stakeholder Impact

• Shareholders experienced dilution from the private placement of 2,626,425 shares to Yuwell (Hong Kong) Holdings Limited. Potential for increased value from strategic growth initiatives and reduced net losses, but also risk of further dilution from future capital raises.
• Employees are subject to stock-based compensation plans. The downsized direct-to-consumer sales team implies some workforce adjustments.
• Customers benefit from new product launches (Simeox, Voxi 5) and an expanded product portfolio through the Yuwell collaboration, potentially offering more options and improved quality of life for patients.
• Suppliers/Vendors: The company continues to rely on a limited number of major vendors for raw materials, which could pose supply chain risks.
• Creditors may view the improved net loss and positive Adjusted EBITDA as favorable, but the negative operating cash flow for the nine months and potential future capital raises (debt or equity) are factors to consider.

Next Steps

• Broaden product portfolio through distribution of Yuwell respiratory products in the U.S. and select other territories.
• Expand and enhance the innovation pipeline through research and development collaboration with Yuwell.
• Accelerate entry of the Inogen brand into the Chinese market.
• Leverage commercial infrastructure and capabilities to market the Simeox device in the United States.
• Continue efforts to obtain market feedback and initiate work towards reimbursement coverage for the Simeox product in the U.S.
• Plan a more extensive launch of the Voxi 5 stationary oxygen concentrator in 2026.
• Continue working through the registration process for products in China.
• Continue to invest in respiratory product offerings to develop innovative products and expand clinical evidence.
• Continue to invest in clinical studies to evaluate expected improvements in clinical, economic, and patient-reported outcomes.
• Expand new products that drive benefits to patients, prescribers, and customers with a clinically relevant pipeline.
• Expand use of products to hypercapnia, shortness-of-breath, and other related disease indications.

Key Dates

Recommendation

While Inogen has shown significant improvement in reducing its net loss and achieving overall revenue growth, driven by strong international and business-to-business sales, there are mixed signals. The strategic collaboration with Yuwell and new product launches (Simeox, Voxi 5) offer promising avenues for future growth and diversification. However, the persistent decline in higher-margin rental revenue and domestic direct-to-consumer sales, coupled with gross margin compression and a negative operating cash flow for the nine-month period, indicate ongoing operational challenges. The company's reliance on a few key vendors and exposure to foreign currency risk also warrant caution. The recent capital raise provides liquidity, but future funding needs could lead to further dilution. Given these factors, a 'Hold' recommendation is appropriate, suggesting investors monitor the execution of strategic initiatives and the stabilization of key revenue segments before making further investment decisions.

Keywords

Portable Oxygen Concentrators, Respiratory Health, Simeox, Airway Clearance, Medical Technology, SEC 10-Q, Financial Results, Revenue Growth, Net Loss Reduction, International Sales, Direct-to-Consumer, Gross Margin, Operating Expenses, Yuwell Collaboration, Voxi 5, Healthcare Industry, Medical Devices, Corporate Governance, Risk Factors, Liquidity, Capital Resources